PGEN on Nasdaq

Precigen, Inc

Logo: https://precigen.com/intrexon/, Non-free logo, via Wikipedia5

American biotechnology company

Precigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 19, 2026.

Overview

1998Founded1

Compare with PROTHENA CORP PUBLIC LTD CO, Janux Therapeutics, Inc. or Zenas BioPharma, Inc., or pick any stock.

  • TickerPGEN on Nasdaq1
  • Industrybiotechnology1
  • HeadquartersGermantown1
  • Websiteprecigen.com
  • Legal formcompany1
  • Incorporated inVA6
  • Business address20374 Seneca Meadows Parkway, Germantown, Md 208766
  • Filer categoryNon-accelerated filer, Smaller reporting company6
  • LEI549300XCWNQU35K64G194
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O Corporation Service Company, 23219 Richmond, United States4
  • Registered withState Corporation Commission, 061548014

See how the biggest companies compare on our leaderboards

Precigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-1141.1%Operating margin8
-2588.2%Net margin8
146.7%Revenue growth, 20258
-1198.6%Return on equity8
4.46×Debt to equity8
-$89.8MFree cash flow8

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Service, Exemplar brought in 49% of the revenue Precigen, Inc broke down this way in fiscal 2025.

  1. Service, Exemplar$3.9M849%up 11% from 2024
  2. Papzimeos$3.4M843%
  3. Product, Exemplar$562.0K87%up 33% from 2024
Products and services by year
Products and services202320242025
Service, Exemplar$5.3M$3.5M$3.9M
Papzimeos$0$0$3.4M
Product, Exemplar$840.0K$422.0K$562.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development37¢$41.3M
  • Selling, general and admin63¢$70.1M
  • Income tax0¢$3.0K

Out of $9.7M in revenue.8 The company lost money this year.

Financial statements

Revenue9108$9.7M in 2025−89% since 2019
0$25.0M$50.0M$75.0M$100.0M2019: $90.7M$90.7M20192020: $32.0M$32.0M2020−65%2021: $14.3M$14.3M2021−55%2022: $26.9M$26.9M2022+89%2023: $6.2M$6.2M2023−77%2024: $3.9M$3.9M2024−37%2025: $9.7M$9.7M2025+147%
Operating income8-$110.5M in 2025+11% since 2023
-$150.0M-$100.0M-$50.0M02023: -$99.8M-$99.8M20232024: -$135.0M-$135.0M2024+35%2025: -$110.5M-$110.5M2025−18%
Net income91011128-$250.6M in 2025−22% since 2019
-$400.0M-$300.0M-$200.0M-$100.0M0$100.0M2019: -$322.3M-$322.3M20192020: -$170.5M-$170.5M2020−47%2021: -$92.2M-$92.2M2021−46%2022: $28.3M$28.3M20222023: -$95.9M-$95.9M20232024: -$126.2M-$126.2M2024+32%2025: -$250.6M-$250.6M2025+99%

Every line of the income statement as filed: the last 3 fiscal years, latest first.8

Period ending2025-12-312024-12-312023-12-31
Total revenues$9.7M$3.9M$6.2M
Research and development$41.3M$53.1M$48.6M
Selling, general and administrative$70.1M$41.3M$40.4M
Impairment of goodwill$3.9M$7.4M$10.4M
Impairment of other noncurrent assets$0$32.9M$445.0K
Total operating expenses$120.2M$139.0M$106.0M
Operating loss-$110.5M-$135.0M-$99.8M
Change in fair value of warrant liabilities-$139.5M$0$0
Interest expense-$3.9M-$6.0K-$468.0K
Interest income$3.2M$1.4M$3.2M
Other income, net$43.0K$5.6M$627.0K
Total other (expense) income, net-$140.1M$7.0M$3.4M
Loss before income taxes-$250.6M-$128.0M-$96.4M
Income tax (expense) benefit-$3.0K$1.8M$458.0K
Net loss-$250.6M-$126.2M-$95.9M
Deemed dividend on preferred stock-$179.0M$0$0
Net loss attributable to common shareholders-$429.6M-$126.2M-$95.9M
Net loss per share attributable to common shareholders, basic (in dollars per share)-$1.37-$0.47-$0.39
Net loss per share attributable to common shareholders, diluted (in dollars per share)-$1.37-$0.47-$0.39
Weighted average shares outstanding, basic (in shares)313.0M shares267.7M shares244.5M shares
Weighted average shares outstanding, diluted (in shares)313.0M shares267.7M shares244.5M shares

Compare Precigen, Inc with another company

The story

In 2015, Intrexon purchased Oxitec, a maker of genetically sterile insects, for $160 million. In April 2019, Intrexon formed a subsidiary called Precigen, with a focus on human gene therapy. Precigen went on to win orphan drug status from the FDA for a CAR-T based therapy (investigational drug name PRGN-3006) to treat acute myeloid leukemia. In early 2020, Intrexon adopted the name of its subsidiary, Precigen, and narrowed its focus to human gene editing. With the change in name the CEO of subsidiary Precigen, Helen Sabzevari, took over leadership of the company from Randal J. Kirk.

From Wikipedia’s article on Precigen, shared under CC BY-SA 4.0.7

Leadership

Who has led Precigen, Inc, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Randal J. Kirk2013–2020
  2. Helen Sabzevari2020–now

Chair

  1. Randal J. Kirk2020

President

  1. Geno J. Germano2016
  2. Helen Sabzevari2017–now

Chief financial officer

  1. Rick L. Sterling2013–2021
  2. Harry Thomasian Jr.2021–now

Chief operating officer

  1. Krish S. Krishnan2013–2016
  2. Andrew J. Last2016–2017
  3. Thomas Bostick2017–2020
  4. Rutul R. Shah2022–now
200020052010201520202025
Board members and other officers (33)

Former names

  • INTREXON CORPMar 9, 2006 to Jan 22, 20206

Timeline

  1. Jan 3, 2020New chief executive Helen Sabzevari becomes CEO16
  2. Aug 7, 2013New chief executive Randal J. Kirk becomes CEO17
  3. 1998Founded Founded1

Filings

401 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 51 major events, 253 insider forms, 20 large holders, 55 other. The latest 20:

  1. Sep 24, 20264 EDGAR
  2. Aug 28, 20264 EDGAR
  3. Aug 26, 2026144 EDGAR
  4. Aug 25, 2026144 EDGAR
  5. Aug 25, 2026144 EDGAR
  6. Aug 25, 20264 EDGAR
  7. Aug 25, 20264 EDGAR
  8. Aug 25, 20264 EDGAR
  9. Aug 25, 20264 EDGAR
  10. Aug 25, 20264 EDGAR
  11. Aug 25, 20264 EDGAR
  12. Aug 21, 2026144 EDGAR
  13. Aug 7, 2026SCHEDULE 13G/A EDGAR
  14. Aug 7, 20264 EDGAR
  15. Aug 6, 2026144 EDGAR
  16. Aug 4, 202610-Q EDGAR
  17. Aug 4, 20268-K EDGAR
  18. Aug 3, 2026144 EDGAR
  19. Aug 3, 20264 EDGAR
  20. Jul 31, 2026144 EDGAR

The 401 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

94 open-market trades by officers, directors and large owners since October 2021: 26 buys and 68 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 26, 2026KINDLER JEFFREY BDirectorSale185,000$7.44$1.4MForm 4
Aug 25, 2026Shah Rutul RChief Operating OfficerSale15,342$7.50$115.1KForm 4
Aug 25, 2026Tennant PhilChief Commercial OfficerSale79,166$7.50$593.7KForm 4
Aug 21, 2026AGEE NANCY HDirectorBuy3,411$7.23$24.7KForm 4
Aug 21, 2026Shah Rutul RChief Operating OfficerSale34,658$7.50$259.9KForm 4
Aug 6, 2026Shah Rutul RChief Operating OfficerSale32,739$6.86$224.6KForm 4
Aug 3, 2026Shah Rutul RChief Operating OfficerSale33,772$6.50$219.5KForm 4
Jul 31, 2026Thomasian Harry Jr.Chief Financial OfficerSale100,000$6.06$606.0KForm 4
Jul 1, 2026Thomasian Harry Jr.Chief Financial OfficerSale171,429$5.53$948.0KForm 4
Jun 29, 2026Thomasian Harry Jr.Chief Financial OfficerSale28,571$5.78$165.1KForm 4
Jun 29, 2026Shah Rutul RChief Operating OfficerSale42,924$5.85$251.1KForm 4
Jun 29, 2026Sabzevari HelenPresident and CEOSale346,836$5.89$2.0MForm 4
May 28, 2026Thomasian Harry Jr.Chief Financial OfficerSale41,884$4.36$182.6KForm 4
May 28, 2026Tennant PhilChief Commercial OfficerSale30,272$4.36$132.0KForm 4
May 28, 2026Shah Rutul RChief Operating OfficerSale42,703$4.36$186.2KForm 4
May 28, 2026Lehr Donald P.Chief Legal OfficerSale29,131$4.36$127.0KForm 4
May 28, 2026Sabzevari HelenPresident and CEOSale119,250$4.36$519.9KForm 4
Mar 30, 2026KIRK RANDAL JDirectorSale4,772,781$3.30$15.8MForm 4
Dec 22, 2025KIRK RANDAL JDirectorSale1,900,036$4.18$7.9MForm 4
Dec 12, 2025KINDLER JEFFREY BDirectorSale235,467$3.63$854.7KForm 4

All 94 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Patient Capital Management, LLC19,036,976$108.5M3.6%+1,219,589
BlackRock, Inc.17,146,921$97.7M0.0%+1,923,730
State Street Corp12,002,465$68.4M0.0%+1,112,341
Diametric Capital, LP9,269,926$52.8M5.6%+2,468,138
Vanguard Capital Management LLC7,906,160$45.1M0.0%+757,164
Tang Capital Management LLC6,417,500$36.6M1.7%No change
Boxer Capital Management, LLC5,150,000$29.4M2.2%+1,650,000
Geode Capital Management, LLC5,019,028$28.6M0.0%+405,599
Iridian Asset Management Llc/ct4,031,963$23.0M7.9%+439,233
Morgan Stanley3,469,628$19.8M0.0%+1,055,306
Occam Crest Management LP3,605,941$19.7M10.8%−663,110
Goldman Sachs Group Inc3,406,456$19.4M0.0%+55,979
Fmr LLC2,570,183$14.7M0.0%+571,587
Vanguard Portfolio Management LLC2,211,172$12.6M0.0%+95,161
First Trust Advisors LP2,014,659$11.5M0.0%New
Bank Of America Corp /de/1,848,414$10.5M0.0%+377,135
Arrowstreet Capital, Limited Partnership1,788,235$10.2M0.0%+1,392,540
Northern Trust Corp1,779,380$10.1M0.0%+167,590
Charles Schwab Investment Management Inc1,515,853$8.6M0.0%+55,233
Woodline Partners LP1,401,945$8.0M0.0%+533
Vanguard Fiduciary Trust Co1,295,948$7.4M0.0%+98,245
Point72 Asset Management, L.P.1,266,679$7.2M0.0%−5,377,682
Franklin Resources Inc1,025,650$5.8M0.0%−1,608,130
Barclays PLC931,368$5.3M0.0%+439,672
Caption Management, LLC900,000$5.1M0.2%+593,384

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63